CUSTOMER SUPPORT CUSTOMER SUPPORT 022-4603 7236

fund search

Individually analyse each scheme and narrow your options further Every minute detail you need to know about scheme of your choice from asset holdings, best and worst performance and fund returns to competitor analysis; is available in the Fund card.
Using this report card, you can gather vital information regarding the future health of the scheme by analysing the top 10 companies and sectors it invests in. You can also track the fund management’s track record and analyse the philosophy behind scheme’s holdings. All the parameters in the fund card are extremely important and can go a long way in helping you decide which scheme to invest your money.

NAV As on Apr-24-2024

Nippon India Pharma Fund(G)-Direct Plan

Top 10 Holdings
Company
(%)
Sun Pharmaceutical Industries Ltd.
14.91
Lupin Ltd.
8.40
Cipla Ltd.
6.51
Apollo Hospitals Enterprise Ltd.
5.79
Dr. Reddy's Laboratories Ltd.
4.75
Gland Pharma Ltd.
4.40
Divi's Laboratories Ltd.
4.36
Zydus Lifesciences Ltd.
4.18
JB Chemicals & Pharmaceuticals Ltd.
3.44
Abbott India Ltd.
3.29
Top 10 Sectors
Sectors
(%)
Pharmaceuticals & Drugs
80.92
Hospital & Healthcare Services
15.13
Business Support
1.11
Asset Allocation
Market Cap Allocation
  Scheme Benchmark ()
Large-Cap 41.43 NA
Mid-Cap 36.47 NA
Small-Cap 19.26 NA

Best and Worst Performance and Ratios

Best Performance in a year
Period Fund (%) Benchmark (%)
Year 23/03/20
to 23/03/21
90.7094.82
Worst Performance in a year
Period Fund (%) Benchmark (%)
Year 08/09/16
to 08/09/17
-15.1210.50
Ratios
Standard Deviation[%] 13.11
Sharpe Ratio [%] 1.18
Turnover Ratio [%] 0.16
Modified Duration
YTM
Riskometer
very high risk

Investors understand that their principal will be at very high risk

Fund Details
Category
Sector Funds
Inception Date (Regular Plan)
05-Jun-04
Inception Date (Direct Plan)
01-Jan-13
Expense Ratio (Direct Plan) %
0.92
Expense Ratio (Regular Plan) %
1.83
Investing Style
Large Growth
Fund Manager
Sailesh Raj Bhan
Scheme Benchmark
S&P BSE SENSEX - TRI
AUM (Rs. in Cr.)
7,125.28
Fund Objective

The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies

Growth Chart of the Scheme Versus Benchmark (SIP value Rs10,000)
Nippon India Pharma Fund(G)-Direct Plan S&P BSE SENSEX - TRI

Performance Comparison with similar Schemes and Benchmark